Results 21 to 30 of about 16,460 (261)

Nanobodies in cancer

Seminars in Immunology, 2021
For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric ...
Elisha R, Verhaar, Andrew W, Woodham, Hidde L, Ploegh   +2 more
openaire   +3 more sources

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Signal Transduction and Targeted Therapy, 2021
Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging.
Fengzhen Mo, Siliang Duan, Xiaobing Jiang, Xiaomei Yang, Xiaoqiong Hou, Wei Shi, Cueva Jumbo Juan Carlos, Aiqun Liu, Shihua Yin, Wu Wang, Hua Yao, Zihang Yu, Zhuoran Tang, Shenxia Xie, Ziqiang Ding, Xinyue Zhao, Bruce D. Hammock, Xiaoling Lu   +17 more
doaj   +1 more source

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein

Cells, 2022
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health.
Qianling Su, Wei Shi, Xianing Huang, Yakun Wan, Guanghui Li, Bengang Xing, Zhi Ping Xu, Hongbo Liu, Bruce D. Hammock, Xiaomei Yang, Shihua Yin, Xiaoling Lu   +11 more
doaj   +1 more source

Immunogenicity Risk Profile of Nanobodies [PDF]

Frontiers in Immunology, 2021
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess unique characteristics, including a minimal size, providing fast pharmacokinetics, high-target specificity, and an affinity in the (sub-)nanomolar range in conjunction with an
Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier, Yann G. J. Sterckx, Yann G. J. Sterckx, Sofie Denies, Benoit Stijlemans, Benoit Stijlemans, Yvon Elkrim, Nick Devoogdt, Vicky Caveliers, Vicky Caveliers, Tony Lahoutte, Tony Lahoutte, Serge Muyldermans, Karine Breckpot, Marleen Keyaerts, Marleen Keyaerts   +17 more
openaire   +5 more sources

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source

Recent advances of nanobody applications in diagnosis and detection

MedComm – Biomaterials and Applications, 2023
Nanobodies (Nbs) are the variable domain of heavy‐chain antibodies derived from the blood of camelids or sharks. Nanobodies are the smallest antibody fragment with intact antigen‐binding ability.
Qianling Su, Wei Shi, Xianing Huang, Shihua Yin, Xiaomei Yang, Xiaoling Lu   +5 more
doaj   +1 more source

Special Issue: Nanobody [PDF]

Antibodies, 2020
Since their first description in 1993 [...]
Patrick Chames, Ulrich Rothbauer
openaire   +3 more sources

Chemogenetic Control of Nanobodies [PDF]

Nature Methods, 2019
ABSTRACT We introduce an engineered nanobody whose affinity to green fluorescent protein (GFP) can be switched on and off with small molecules. By controlling the cellular localization of GFP fusion proteins, the engineered nanobody allows to study their role in basic biological processes, an approach that should be applicable to ...
Farrants, Helen, Tarnawski, Miroslaw, Müller, Thorsten G., Otsuka, Shotaro, Hiblot, Julien, Koch, Birgit, Kueblbeck, Moritz, Kräusslich, Hans-Georg, Ellenberg, Jan, Johnsson, Kai   +9 more
openaire   +3 more sources

Tyrosinase-Mediated Synthesis of Nanobody–Cell Conjugates [PDF]

, 2022
A convenient enzymatic strategy is reported for the modification of cell surfaces. Using a tyrosinase enzyme isolated from Agaricus bisporus, unique tyrosine residues introduced at the C-termini of nanobodies can be site-selectively oxidized to reactive ...
Daniel K. Nomura (198023), Johnathan C. Maza (1416832), Noah X. Hamlish (12906839), Derek M. García-Almedina (11942742), Lydia E. Boike (12906836), Matthew B. Francis (425831)   +5 more
core   +4 more sources

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Journal of Immunology Research, 2020
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited.
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu   +15 more
doaj   +1 more source